Savara, Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program, MOLBREEVI, is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary eFlow Nebulizer System supplied by PARI Pharma GmbH. The company has submitted a biologics license application to the U.S. Food and Drug Administration and has received Fast Track, Breakthrough Therapy, and Orphan Drug Designations from the FDA, as well as Orphan Drug Designation from the European Medicines Agency. Savara outsources its manufacturing operations, utilizing Fujifilm Diosynth Biotechnologies for drug substance production and Patheon UK Ltd. for drug product manufacturing. The company’s strategy involves advancing the MOLBREEVI program through regulatory approval and establishing a commercial supply chain.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage savarapharma.com
Sector Healthcare IR page investors.savarapharma.com/overview/default.aspx
Tags
rare respiratory diseases, inhaled biologics, autoimmune pulmonary alveolar proteinosis, gm-csf, orphan drugs, drug-device combination, clinical-stage, MOLBREEVI, molgramostim, eFlow Nebulizer System, PARI Pharma GmbH, Fujifilm Diosynth Biotechnologies, GEMA Biotech S.A., Patheon UK Ltd., ThermoFisher Scientific Inc.
Press page —

Metrics

Valuation  
Market cap $ 1.061B
Market cap (USD) $ 1.061B
P/E -8.46
PEG —
P/BV 9.83
P/S —
P/OCF -8.14
P/FCF -8.10
Dividend yield —
Turnover / mcap —
Returns  
ROE -63.5%
ROI -51.0%
ROIC -39.8%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 28.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score -85.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Revenue — — — — — 257K 0 400K 0 128K 0 0 — 0 — 488.959K — — — — —
Net profit -118.837M -95.881M -54.698M -38.15M -43.014M -49.615M -78.173M -61.516M -29.797M -36.1M -39.842M -28.702M -21.48M -15.559M -13.26M -8.451M — — — — —
Free cash flow -101.059M -89.113M -51.357M -34.563M -40.138M -39.883M -45.271M -39.416M -28.729M -37.275M -33.114M -24.792M -17.836M -14.185M -13.879M -8.37M — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Share price 6.03 3.07 4.7 1.55 1.24 1.15 4.48 7.57 14.84 — — — — — — — — — — — —
Price performance 12m 0.96 -0.35 2.03 0.25 0.08 -0.74 -0.41 -0.49 — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — — — — 8.33M — — 0.00 0.00
Borrowings, non-current (USD) — — — — 25.1M 17.3M 26.1M 26.3M 26.6M 29.9M
Lease liabilities (USD) — — — 700,000 300,000 300,000 110,000 400,000 300,000 85,000
Cash and deposits (USD) 8.54M 22.1M 24.3M 49.8M 22.9M 34M 52.1M 26.6M 15.1M 33.2M
Right-of-use assets (USD) — — — 700,000 200,000 300,000 100,000 400,000 200,000 100,000
Net debt (borrowings + leases - cash) (USD) — — — — 2.22M -8.06M -25.9M 163,000 11.8M -3.19M
Cash flow detail
Operating cash flow (USD) -37.3M -28.2M -39.3M -45.1M -39.8M -40.1M -34.6M -51.1M -89.1M -101M
Purchases of property, plant and equipment (USD) -8,000 -495,000 -141,000 -148,000 -47,000 -57,000 -9,000 -296,000 -25,000 -22,000
Change in payables (cash effect) (USD) -1.97M 159,000 — — — — — — — —
Interest paid (cash effect) (USD) -1.21M -733,000 -1.41M -2.1M -2.47M -1.97B -1.61M -2.04M -2.12M -3.2M
Income taxes paid (cash effect) (USD) — — — — — — — — — 0.00
Share-based compensation (USD) 2.64M 552,000 3.74M 4.44M 5.11M 3.26M 2.04M 4.18M 9.86M 14.4M
Free cash flow (OCF - PPE - intangibles) (USD) -37.3M -28.7M -39.4M -45.3M -39.9M -40.1M -34.6M -51.4M -89.1M -101M
Income detail
Research and development expense (USD) 20.8M 18.5M 37.2M 38.8M 35M 29M 27.9M 44.3M 78M 81.4M
↳ 5y CAGR +29.3% +18.0% +23.6% +14.8% +4.4% +6.9% +8.5% +3.6% +15.0% +18.4%
Total comprehensive income (USD) -36.1M -28.2M -62.3M -78.4M -48.7M -44M -38.8M -54.4M -96.4M -118M
Comprehensive income to owners (USD) -36.1M -28.2M -62.3M -78.4M -48.7M -44M -38.8M -54.4M -96.4M -118M
Reported Mar 6, 2017 Mar 13, 2019 Mar 13, 2019 Mar 12, 2020 May 13, 2021 Mar 30, 2022 Mar 30, 2023 Mar 7, 2024 May 13, 2025 Mar 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Savara Announces New Employment Inducement Grant Bull 0 Bear 0 Routine

August 20, 2026

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.

On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.

The options have an exercise price of $5.37 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16th of the number of shares subject to the option on each quarterly anniversary of the employee’s first day of employment, subject to the employee’s continued employment on each such vesting date. The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, subject to the employee’s continued employment on such vesting date.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com , and LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/ ).

*MOLBREEVI is the proposed trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.

Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
[email protected]

Source: Savara Inc.

View All News

August 11, 2026

  • Download (opens in new window)

  • MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026

  • MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively

  • Data Presented at ATS Showed Molgramostim Demonstrated Continuous Long-term Improvements in Lung Function and Respiratory Health-Related Quality of Life

  • European and Australian Patent Offices Granted MOLBREEVI Liquid Formulation Patents, Providing Protection until March 2041

  • ~$173M in Cash and Short-Term Investments as of June 30, 2026, Plus up to ~$150M of Non-Dilutive Capital Upon FDA Approval of MOLBREEVI, Positions the Company Well for Launch

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update.

“While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term opportunity,” said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara. “Our focus is on the potential launch of MOLBREEVI in the U.S., supported by a strong balance sheet to ensure commercial readiness.”

Second Quarter Financial Results (Unaudited)

Savara's net loss for the second quarter of 2026 was $40.2 million, or $(0.16) per share of which $7.8 million was related to non-cash share-based compensation expense compared with a net loss of $30.4 million, or $(0.14) per share of which $2.7 million was related to share-based compensation expense, for the second quarter of 2025.

Research and development expenses increased by $1.2 million, or 5.8%, to $22.0 million for the three months ended June 30, 2026 from $20.8 million for the three months ended June 30, 2025. This increase was primarily due to $2.0 million of higher personnel costs, mainly related to increased stock-based compensation expense, partially offset by the performance of tasks related to our MOLBREEVI program, which included a decrease of $0.2 million of costs related to our chemistry, manufacturing, and controls activities, primarily driven by activity at our drug substance manufacturer, and a decrease of $0.6 million of costs related to regulatory affairs and quality assurance consulting.

General and administrative expenses increased by $8.3 million, or 78.2%, to $19.0 million for the three months ended June 30, 2026 from $10.7 million for the three months ended June 30, 2025. The increase was primarily attributable to $7.5 million higher personnel costs, driven by increased stock-based compensation expense as well as increased headcount as we build out our commercial team in support of our planned product launch, in addition to an increase of $0.8 million in certain commercial activities. These investments reflect our strategy to establish the commercial infrastructure necessary to support an effective and timely launch.

As of June 30, 2026, the Company had cash, cash equivalents and short-term investments of ~$173.0 million and debt of ~$30.1 million.

About Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by autoantibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas transfer, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.

About Savara

Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and LinkedIn .

*MOLBREEVI is the proposed trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.

Forward-Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements include, but are not limited to, statements related to the PDUFA target action date, the timing of regulatory actions by the EMA and MHRA, the duration of patent protection, that Savara has access to up to ~$150M of non-dilutive capital upon FDA approval of MOLBREEVI, that the U.S. represents our nearest-term opportunity, and that our focus is on the potential launch of MOLBREEVI in the U.S., supported by a strong balance sheet to ensure commercial readiness. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risks associated with our ability to successfully develop, obtain regulatory approval for, and commercialize MOLBREEVI for autoimmune PAP; changes to applicable laws and regulations; the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations; the availability of sufficient resources for Savara’s operations and to conduct or continue planned clinical development programs; and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Financial Information to Follow

Savara Inc. and SubsidiariesCondensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except for share and per share amounts)Unaudited
Three months ended Six months ended
June 30, June 30,
2026 2025 2026 2025
Operating expenses:
Research and development $ 21,951 $ 20,751 $ 45,349 $ 39,910
General and administrative 18,986 10,655 34,554 19,901
Depreciation and amortization 28 34 52 63
Total operating expenses 40,965 31,440 79,955 59,874
Loss from operations (40,965 ) (31,440 ) (79,955 ) (59,874 )
Other income (expense), net: 737 1,039 2,443 2,834
Net loss attributable to common stockholders $ (40,228 ) $ (30,401 ) $ (77,512 ) $ (57,040 )
Net loss per share - basic and diluted $ (0.16 ) $ (0.14 ) $ (0.31 ) $ (0.26 )
Weighted average shares - basic and diluted 253,569,891 216,431,348 253,426,018 216,289,923
Other comprehensive (loss) gain (105 ) 416 (447 ) 534
Total comprehensive loss $ (40,333 ) $ (29,985 ) $ (77,959 ) $ (56,506 )
Savara Inc. and SubsidiariesCondensed Consolidated Balance Sheet Data(in thousands)(Unaudited)
June 30, December 31,
2026 2025
Cash, cash equivalents, and short-term investments $ 173,034 $ 235,702
Working capital 160,718 221,220
Total assets 192,138 253,436
Total liabilities 48,478 50,303
Stockholders’ equity: 143,660 203,133

Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
[email protected]

Source: Savara Inc.

View All News

July 30, 2026

-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043 --

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has also granted a patent, No. 62/990,810, covering the liquid formulation of MOLBREEVI, and securing protection in Australia through the same date.

“These patents further strengthen the Company’s intellectual property portfolio for MOLBREEVI, providing an additional layer of defense in markets with no approved alternatives,” said Kate McCabe, Chief Legal Officer, Savara. “Together, these patents reflect the strength of our liquid formulation IP across key ex-US markets. In parallel, we are advancing equivalent patent filings in the U.S., including a patent for the drug-device combination, with the aim of securing comprehensive protection across major commercial territories.”

MOLBREEVI, delivered via the proprietary eFlow® Nebulizer System, has been granted Fast Track and Breakthrough Therapy Designations by the U.S. Food and Drug Administration (FDA), Orphan Drug Designation by the FDA and by the European Medicines Agency (EMA), and Innovation Passport (IP) and Promising Innovative Medicine (PIM) designations by the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of autoimmune PAP.

About Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via the proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and LinkedIn.

*MOLBREEVI is the proposed trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.

Forward-Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements include, but are not limited to, statements related to the impact of the patents and the duration of protection and that we are advancing equivalent patent filings in the U.S. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risks associated with our ability to successfully develop, obtain regulatory approval for, and commercialize MOLBREEVI for autoimmune PAP; the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations; the availability of sufficient resources for Savara’s operations and to conduct or continue planned clinical development programs; and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
[email protected]

Source: Savara Inc.

View All News

Prompts

Savara, Inc. (ticker SVRA), listed in United States.

Company History

Date Change Detail
Apr 27, 2017 Renamed MAST THERAPEUTICS, INC. → SAVARA INC
Mar 12, 2013 Renamed ADVENTRX PHARMACEUTICALS INC → MAST THERAPEUTICS, INC.
Feb 9, 2004 Renamed BIOKEYS PHARMACEUTICALS INC → ADVENTRX PHARMACEUTICALS INC

ETFs Holding Savara, Inc.

ETF Weight in ETF Shares Market value As of
LFSC 2.87% 673,019 $ 3.628M Aug 31, 2026
JSML 0.62% 409,369 $ 2.235M Jul 31, 2026
FSEG 0.08% 775 $ 4,774.00 Jun 30, 2026
VFMO 0.05% 183,606 $ 989.636K Aug 31, 2026
RESM 0.02% 124 $ 763.84 Jun 30, 2026
FESM 0.01% 103,925 $ 640.178K Jun 30, 2026
MSSM 0.00% 4,014 $ 21.635K Aug 31, 2026
DFAS 0.00% 23,796 $ 112.317K Nov 12, 2026
AVSC 0.00% 1,747 $ 7,800.36 Nov 16, 2026